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One of the striking features of multiple myelomais the frequent occurrence of 
a homogeneous plasma globulin in high  concentration. Although this aspect of 
the disease has received a great deal of attention, many fundamental questions 
about the plasma protein  abnormalities  remain  unanswered.  For example,  it 
has not yet been established whether the myeloma protein in plasma is produced 
by the tumor cells themselves or is a response  of other tissues to the effect of 
the tumor.  None of the evidence to date clearly differentiates between these 
two possibilities  (1-7). 
With the report by Potter, Fahey, and Pilgrim (6) of the mouse plasma cell 
neoplasm X5563,  which  is  associated with  a  high  concentration  of a  homo- 
geneous gamma globulin  in the plasma and other pathological changes  similar 
to multiple myeloma in man, an experimental approach to the problem of the 
origin  of the myeloma protein became feasible.  The present study was under- 
taken to ascertain by means of in vivo labelling  whether cells of the tumor form 
the myeloma protein. 
EXPERIMENTAL 
Design of the Experiments.--In the event that myeloma protein is synthesized 
by the tumor cells, it can be assumed that, following  the administration  of a 
labelled  amino  acid,  the myeloma protein  in  the tumor will be more highly 
labelled  and attain its peak radioactivity earlier than that in the plasma; i.e., 
that a precursor-product relationship will be demonstrated (8). 
Uniformly labelled L-lysine-C  m  in a  dose of 1 to 2 microcuries (0.078 micromoles/miero- 
curie) was injected intravenously v/a the tail vein into mice bearing the plasma cell tumor 
X5563  and the animals were sacrificed at intervals varying from  10  minutes to  16 hours. 
The plasma and tumor myeloma proteins were isolated from each animal, and the specific 
activity of the lysine in each sample was measured. 
The mice used in these experiments were from  C3Hf/Lw,  C3Hf/He  colonies, maintained 
* Present address: Presbyterian Hospital, New York. 
1 The L-lysine-C  a4 was obtained from Nuclear Chicago, Chicago. 
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at the National Cancer Institute. The mice were fed Derwood pellets and water ad libitum 
and were housed in plastic cages with 6 to 8 mice per cage. The plasma cell neoplasm X5563 
was  transferred  by the trochar  method  into the right  axillary subcutaneous  space, which 
resulted  in  a  local, well  vaseularized  reddish-purple  tumor  consisting  of  discrete  masses 
of typical plasma cells (9).  Studies were conducted from about 30 to 60 days after tumor 
transplantation, when the tumor had attained a  size which was distinctly palpable. 
Isolation  of Plasma  and  Tumor  Mydoma  Protein.--Blood  obtained  from  heparinized 
animals by cardiac puncture was centrifuged and the plasma separated.  Total plasma pro- 
tein was determined by the biuret method, and the percentage of myeloma protein by paper 
electrophoresis, as described elsewhere (10). 
The tumor was excised from the subcutaneous  tissue space immediately after the blood 
specimen was obtained,  and was weighed and  cooled on ice. It was then quickly minced 
with scissors and washed five times with cold isotonic saline. (In some instances the tumors 
were frozen promptly after removal and processed at a  later date.)  The minced tumor was 
then frozen rapidly. Approximately 2 to 3 minutes elapsed between excision of the tumor 
and the freezing of the minced tissue. The frozen mince was homogenized with approximately 
twice its weight of cold isotonic saline in a  Potter-Elvehjem homogenizer for 8 minutes at 
4°C., using a power-driven pestle. Smears of the homogenate were examined microscopically 
and were found  to be virtually free of intact  cells.  The homogenate was then frozen and 
thawed,  resulting in flocculation of considerable  cellular material  which was  removed by 
centrifugation at 3500 g for 30 minutes at 4°C. A clear supernatant  solution containing the 
myeloma protein was retained. 
The myeloma proteins from the plasma and the tumor extract were isolated by column 
chromatography  using the anion-exchange adsorbent,  diethylaminoethyl cellulose (DEAE- 
cellulose)  (I1), employing a modification of procedures described in detail elsewhere (10, 12). 
The plasma or tissue extracts to be chromatographed were dialyzed against 0.01 ~  sodium 
phosphate  buffer of pH8 for 12 to 15 hours at 4°C. The resulting solution was centrifuged 
to remove the small amount of precipitate formed at this low ionic strength. The supernatant 
protein solution (equivalent to 0.2 to 0.8 ml. of plasma or 1 to 3 gin. of tumor) was applied 
to a DEAE-cellulose column (9 X  300 ram.) and the proteins eluted at 4°C. with phosphate 
buffer of pH 8 and continuously increasing ionic strength. The starting buffer of 0.01 K so- 
dium phosphate was contained in a 100 ml. spherical chamber and a solution of 0.1 ~  sodium 
phosphate buffer--0.2 M sodium chloride was added continuously from a 50 ml. Erlenmeyer 
flask reservoir. The protein concentration of the effluent fractions was estimated by optical 
density at 280 nag using a Beckman model DU spectrophotometer. 
Typical column chromatograms of plasma and  tumor extract from X5563-bearing mice 
are illustrated in Fig. 1. The largest peak in each pattern was found on paper electrophoresis 
to contain only myeloma protein  (homogeneous gamma globulin peak).  In three separate 
determinations the yield of myeloma protein from tumor was 4.7,  5.0, and 5.4 mg. per gin. 
of tumor. 
Specific A ctivity Measurements.--The specific activities of the purified proteins were deter- 
mined by measuring the specific activity of lysine isolated from each  sample  as  its e-dini- 
trophenyl derivative. The protein was precipitated  from the column eluate  solution with 
an equal volume of  10  per cent trichloracetic acid. The precipitated  protein was  reacted 
with fluorodinitrobenzene using the method  described by Porter  (13)  and  hydrolyzed  for 
16 hours  with  5.7  ~  HC1  at  110  °  C. in a  sealed tube. The hydrolysate was taken to dry- 
ness in a vacuum desiccator and, after initial extraction of the residue with ether to remove 
dinitrophenol and N  terminal amino acids, the remaining DNP amino acids were taken up 
in acetone acidified with HC1. e-DNP lysine was isolated from the acetone solution by the 
one-dimensional paper chromatography  system of Blackburn and Lowther (14),  and eluted 
from the paper with an acetone-water mixture. The radioactivity of an aliquot (0.1  to 0.5 D. NATHANS,  J.  L. I~A]KEY, AND  IM'.  POTTER  123 
micromoles) of the e-DNP lysine solution was measured as an  "infinitely thin" film on a  4 
cm.  diameter glass disc in a  windowless gas flow counter.  2 The probable error of counting 
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FIO. 1. Column chromatograms of X5563 tumor extract, X5563 plasma, and normal mouse 
serum.  The same procedure was employed in each chromatogram and is described in the 
Experimental section. The label A indicates the site of elution of albumin in the normal serum 
and X5563 plasma chromatograms. 
was generally less than 2 per cent for each sample. The concentration of e-DNP lysine was 
determined on another aliquot  by measuring the absorption at  360 m# and utilizing pub- 
lished data for the extinction coefficient (15). 
We  are  indebted to  Dr.  James  C.  Reid,  Laboratory  of  Physiology,  National  Cancer 
Institute, for the use of radioactive counting facilities. 124  FORMATION OF  MYELOMrA PROTEIN" 
For measurement  of the specific  activity of free lysine in a  tumor,  a  portion of whole 
tumor homogenate was added without delay to an equal volume of l0 per cent trichloracetic 
acid and  lysine isolated from the supernatant  solution as its di-DNP derivative using the 
two dimensional paper  chromatography  system  of Levy (15).  The  specific  activity of the 
eluted di-DNP lysine was determined in the same manner as described for the e-DNP deriva- 
tive, except that absorption at 355 mg was used to calculate the concentration. 
The possibility that  adsorbed  lysine might contribute  to the measured  specific  activity 
of the tumor myeloma protein,  particularly when the activity of free lysine in the tumor 
was high, was investigated. When 0.2 microcuries of ~lysine-C  14 was added to tumor homog- 
enate and the homogenate handled in the manner  described  above,  the  e-DNP  lysine ob- 
tained from the isolated tumor myeloma protein had no radioactivity. 
To calculate the actual  specific  activity (s.a.)  of newly formed myeloma protein in the 
tumor it was necessary to determine the extent to which the tumor myeloma protein prepara- 
tion contained circulating myeloma protein. This was done in the following manner. Serum 
containing labelled myeloma protein was obtained from an animal with the X5563 tumor 4 
hours  after  intravenous  injection of L-lysine-C li.  0.8  milliliter of this  serum  was  injected 
intravenously into another X5563 tumor-bearing mouse and the tumor and plasma myeloma 
proteins were isolated from the recipient 21 hours later. In the recipient animal the specific 
activity of the tumor myeloma protein was approximately two-thirds (0.68) that of the plasma 
myeloma protein. Therefore, the measured specific  activities of the tumor myeloma protein 
preparations were corrected as follows: Actual s.a.  =  (3  X  measured s.a.)  -  (2  X  plasma 
myeloma  protein  s.a.  in  the same animal).  This  correction  can  only  be  considered  ap- 
proximate,  but  better  representative  of the  probable  difference  between  the  tumor  and 
plasma  myeloma protein  than  the uncorrected data. Such a correction in no way alters the 
qualitative nature of the results. 
Finally, all specific  activity values (free lysine, tumor protein, and plasma protein)  were 
corrected to a constant dose of C14-1ysine per unit body weight (1.0/zc./30 gin.). 
Comparison of the Specific Activities  of the Myeloma Protein in Different Animals.--The 
specific  activities of the tumor and  plasma myeloma protein were determined at the same 
time after C14-1ysine injection in each animal and hence are directly comparable. However, 
in order to compare the specific activities of the myeloma proteins in different animals with- 
out further correction factors, certain assumptions must be made: first, that a constant dose 
of tracer lysine per unit body weight results in the same specific  activity of free lysine in 
the tumors; second, that  the turnover time of the plasma myeloma protein is the same in 
each animal; third, that the plasma myeloma protein pool size per gram of tumor is approx- 
imately constant.  The first two assumptions were accepted as being approximately correct. 
The  third  assumption  is substantiated  by the data  shown  in Fig.  2,  which indicate  that 
the pool size  of the plasma  myeloma protein is approximately proportional to the tumor 
weight. The fact that the line does not pass through the origin may be due to the presence 
of necrotic tissue in the larger tumors and  to low estimates of extracellular fluid volumes 
in animals with larger tumors. 
Amino  Acid  Composition of the Myeloma  Protein.--The amino acid  composition of the 
serum myeloma protein prepared by column chromatography was determined by two-dimen- 
sional paper chromatography  of the dinitrophenyl amino acids according to the method of 
Levy (15).  Hydrolysis was carried out with glass-distilled 5.7  N HC1  (5  ml.  HC1  solution 
per 3.5 rag.  of protein) in sealed tubes at ll0°C, for 19, 36, and 72 hours. Each hydrolysate 
was  treated  with  fluorodinitrobenzene  and  chromatograms  of  the  resulting  DNP  amino 
acids were run in triplicate. Tryptophan and  tyrosine contents were determined separately 
by the spectrophotometric method of Goodwin and Morton (16) using the intact protein. D. NATHANS, .L L. FAEEY, AND M. POTTER  125 
RESULTS 
Properties  of the  Plasma  and  Tumor  Myeloma  Proteins.--The  tumor  and 
plasma  myeloma proteins prepared  by column chromatography were shown 
to be homogeneous and to have identical properties. Both proteins appeared 
homogeneous on column chromatography and were eluted at the same effluent 
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FIG. 2, Relationship of tumor weight to extracellular myeloma protein pool (plasma con 
centration X estimated volume of distribution of 2 mi./25 gin. total body weight.) The line 
was determined by the method of least squares. 
volume (Fig. 1). Both preparations were homogeneous by paper electrophoresis 
and had the same electrophoretic mobility (Fig. 3). Ultracentrifugal analyses 
indicated  a  homogeneous protein in  each case with essentially identical  $20 
values, 6.4 for the plasma protein and 6.6 for the tumor protein (Fig. 3).  s 
The amino  acid  composition of the  myeloma protein,  determined  on  the 
serum protein isolated by column chromatography, is presented in Table I. 
a Ultracentrifugal analyses were carried out by Mr. F. J.  Gutter of the Laboratory of 
Biochemistry, National Cancer Institute. 126  •  ORMATION  OF MYELOMA  PROTEIN 
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FIG.  3. Electrophorefic and ultracentrifugal analysis of the tumor myeloma protein and 
the plasma myeloma protein preparations obtained by column chromatography.  (On each 
of  the  paper  electrophoretic densitometer tracings is  a  peak  (A)  representing  crystalline 
bovine albumin that was applied prior to the  myeloma protein sample in order to  detect 
more readily any minor components present (10).  The arrows indicate the point of applica- 
tion. Ultracentrifugation was carried out at 59,780 R.p.x¢. and these photographs were ob- 
tained at  75 minutes.  Protein concentrations were approximately  0.6 gm.  per cent in the 
ultracentrifugatiou samples.) 
TABLE  I 
Amino Acid Composition of tke Serum Myeloma Protein Isolated by Column Chromatography 
Amino Acid 
Alanine .................... 
Arginine  ................... 
Aspartic +  glutamic acid .... 
Leucine +  isoleucine ........ 
Cystine .................... 
Histidine ................... 
Glycine .................... 
Lysine ...................... 
Methionine ................. 
Phenylalanine .............. 
Proline ..................... 
Serine ..................... 
Threonine  ................... 
Tryptophan ................. 
Tyrosine ................... 
Valine  ..................... 
Optical densities of DNP-amino 
acids* 
19 hrs. 
0.257 
1.24 
0.965 
0.095 
0.266 
0.566 
0.723 
0.031 
0.332 
0.906 
0.938 
0.832 
0.878 
36 hrs. 
O. 293 
0.268 
1.27 
1.07 
0.011 
O. 236 
0.553 
0.768 
0. O52 
0.346 
0.936 
0.969 
0.882 
0.904 
72 hrs. 
0.356 
0.175 
1.48 
1.05 
0.022 
0.186 
0.607 
0.021 
0.324 
0. 870 
0. 232 
0.485 
0.963 
Mole  Gin. amino acid§ 
fraction~;  tO0 gin. protein 
0.0407  3.34 
0.0298  4.74 
O. 153  19.6 
O. 124  15.0 
0.0056  1.23 
0.0452  6.41 
0.0655  4.50 
0.0514  6.85 
0.0066  0.91 
0.0374  5.66 
0.0913  9.63 
0.0984  9.45 
0.0944  10.3 
3.3011 
4.7311 
0.0998  10.6 
* Each value is the average of a triplicate determination. 
:~ Calculated  from  the  maximal O.D.  using Levy's  factors  (15). 
§ Calculated  from  the  mole  fractions. 
[I Determined  spectrophotometrically  on  the  intact  protein  (16). D.  NATHANS,  J.  L.  FAH~Y)  AND  M.  POTTER  127 
Formation of Mydoma Protein.--Time  curves for the specific  activities of 
tumor and plasma myeloma proteins following intravenous  Clqysine injection 
are illustrated in Fig. 4. The marked differences in specific activity of the tumor 
and  plasma  proteins  in  the  same  animal  clearly demonstrate  that  the  two 
proteins are in different pools.  These curves meet the criteria for a precursor- 
product  relationship  as  derived  by Zilversmit,  Entenman,  and  Fishler  (8); 
that is, the specific activity of the tumor myeloma protein (precursor) exceeds 
that of the plasma myeloma protein (product) in the early part  of the curve, 
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Fro.  4.  Specific activity--time curves for the tumor and the plasma myeloma proteins 
following intravenous injection of L-lysine-C  14 at 0 time, 
is equal to the specific activity of the plasma protein at the point of maximum 
of the latter, and is less than the specific activity of the plasma protein beyond 
this. These results indicate that myeloma protein is synthesized in the tumor. 
Transit Time of the Mydoma Protdn.--The transit  time is the interval be- 
tween intravenous  injection of a  labelled amino  acid  and  the appearance of 
labelled plasma protein in the circulation (17). In Fig.  5 the specific activity- 
time curves of the free lysine in the tumor,  the tumor myeloma protein,  and 
the plasma myeloma protein are shown during the first 90 minutes after C  l*- 
lysine injection. The transit  time of the plasma myeloma protein is approxi- 
mately 30 minutes.  However, there is little or no delay in the appearance of 
isotope in  the free lysine of the  tumor  and  in  the  tumor myeloma protein. 128  FORMATION  0]~ EYELOM.A  PROTEIN 
Hence most of the transit  time would seem to represent processes occurring 
after actual synthesis of the myeloma protein. 
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FIG. S. Specific  activity--time  curves for free lysine of the tumor, tumor myeloma pro- 
tein, and plasma myeloma protein during the first 90 minutes following intravenous injec- 
tion of ~lysine-C  ~. 
The asterisks indicate values with a probable counting error of 15 per cent. 
DISCUSSION 
Previous data bearing on the origin of the serum myeloma protein are gen- 
erally consistent with the synthesis of this protein by the tumor cells.  One ap- 
proach has correlated the decline of serum myeloma protein  with destruction 
or extirpation of the neoplasm (2, 3,  7).  Although this has been accepted  as 
evidence for myeloma protein synthesis in the tumor, it could equally well be 
accounted for by the removal of a stimulus for synthesis elsewhere in the body. D. NATHANS~ ~. L. FAHEY, AND M. POTTER  129 
Evidence  of a second type is based  on the demonstration of a protein in ex- 
tracts of plasma cell tumors (or marrow of patients with multiple  myeloma) 
with characteristics  of the serum myeloma globulin (1, 3, 4, 6). However,  too 
few properties  (i.e.  electrophoretic  mobility or sedimentation constant) of the 
protein preparations have been compared  to establish  identity. Furthermore, 
the "tumor myeloma protein" may actually have been largely plasma or inter- 
stitial fluid protein incompletely washed from the tumor tissue. 
In the present study, the protein obtained from the X5563 tumor was iden- 
tical with the plasma myeloma protein on electrophoretic,  chromatographic, 
and ultracentrifugal analyses.  That the "tumor myeloma protein" is not en- 
tirely residual  plasma protein is  clearly  shown  by the marked difference in 
specific activities  of the two proteins  in the same  animal  2 hours  after 0 4- 
lysine injection, indicating that they are in different protein pools. 
The specific activity-time curves, which  have the characteristic  precursor- 
product relationship,  demonstrate that myeloma protein is synthesized in the 
cells of the plasma cell tumor. Although the data do not exclude the possibility 
that some of the myeloma protein may be synthesized  in tissues other than 
the tumor, it seems unlikely that this specific protein would be formed both 
by the neoplastic ceils and by other tissues of the host. The correlation between 
tumor weight and the amount of plasma myeloma protein, and  a  rough ap- 
proximation of the rate of synthesis of myeloma protein by the tumor, v/z. 14 
rag. per gm. tumor per day,  4 suggest that the plasma cell tumor is the major 
site, or perhaps  the only site, of myeloma protein formation. 
The finding of a  transit time of approximately 30 minutes for the myeloma 
protein of the plasma is in  agreement with  the  values  obtained for plasma 
proteins in several mammalian species under various experimental  conditions 
(17-20).  What accounts  for the transit time is not clear. It includes the time 
for entrance of injected labelled amino acid into the cell, intracellular synthesis 
of the protein, and release of protein into the general circulation.  The short 
delay in the appearance  of labelled tumor myeloma protein found in this study 
would indicate that the time required  for entrance of the labelled amino acid 
into the cell and its appearance  in new protein cannot account for more than 
a  fraction of the transit time of myeloma protein.  The major portion of the 
transit time seems to represent  processes concerned with release of the newly 
formed protein  from the  cell and  its  entrance into  the general  circulation, 
rather than protein synthesis per se. 
4  Calculated from the estimated  t~ of the tumor myeloma  protein (2 hours) and the con- 
centration of tumor myeloma protein (1.7 rag. per  gin. tumor) as  follows:-- 
24  hours 
X  1.7 rag.  2 hours/0.69? 130  ]?ORMATION 0]~ M'YELOMA  PROTEIN 
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The  origin  of the myeloma protein  found in mice bearing  the plasma  cell 
tumor X5563 has been investigated.  Specific activity-time  curves of the mye- 
loma proteins isolated from the tumor and from the plasma of these animals 
were  compared  following  intravenous  injection  of  L-lysine-C  14.  The  results 
indicate that myeloma protein is synthesized in the plasma cell tumor. 
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